ketendoКлиническая и экспериментальная тиреоидологияClinical and experimental thyroidology1995-54722310-3787Endocrinology Research Centre10.14341/ket20128427-30ketendo-4454Research ArticleСтатьиArticlesНарушение функции щитовидной железы у пациентов после лечения лимфомы ходжкинаThyroid function after therapy for Hodgkin's diseaseBobrovaE I

аспирант кафедры эндокринологии ГБОУ ВПО “Первый МГМУ им. И.М. Сеченова” МЗ РФ

-SotnikovV M-PavlovaM G

канд. мед. наук, ассистент кафедры эндокринологии ГБОУ ВПО “Первый МГМУ им. И.М. Сеченова” МЗ РФ

-FadeyevV V

доктор мед. наук, заместитель директора ФГБУ “Эндокринологический научный центр” МЗ РФ, профессор кафедры эндокринологии ГБОУ ВПО “Первый МГМУ им. И.М. Сеченова” МЗ РФ

walfad@mail.ru20121512201284ТОМ 8, №4 (2012)2730Copyright © Bobrova E.I., Sotnikov V.M., Pavlova M.G., Fadeyev V.V., 20122012Bobrova E.I., Sotnikov V.M., Pavlova M.G., Fadeyev V.V.Bobrova E.I., Sotnikov V.M., Pavlova M.G., Fadeyev V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.cet-endojournals.ru/jour/article/view/4454

Лимфома Ходжкина (ЛХ) – пример реальных успехов современной медицины в лечении онкологических заболеваний. Эта смертельная в прошлом болезнь в настоящее время полностью излечивается у 80–90% больных, получавших терапию в специализированных клиниках [4]. Достигнуты значительные успехи и в реабилитации пациентов с ЛХ, что подтверждается результатами социологических исследований. По данным опросов, качество жизни у излеченных больных не хуже, чем в общей популяции [1, 5]. ЛХ не относится к числу распространенных заболеваний. В США в период с 2005 по 2009 г. зарегистрировано 7500 первичных больных в год (3,2 на 100 тыс. среди мужчин и 2,5 на 10 тыс. среди женщин), причем 12,8% из них составили молодые люди до 20 лет. В России в 2009 г. зарегистрировано 2570 пациентов, что составило 15,2% всех первичных больных со злокачественными новообразованиями лимфатической и кроветворной ткани, или 0,7% от общего числа онкологических больных [4]. Последние эпидемиологические исследования в США, охватывающие более чем полувековой период (1935–1998), позволили выявить достоверный рост заболеваемости ЛХ у подростков и молодых людей до 30 лет [2]. В числе причин, способствующих росту заболеваемости, можно назвать эпидемию ВИЧ-инфекции, распространенность инфекционного мононуклеоза и ряд других факторов.

ReferencesWettergren L., Björkholm M., Langius-Eklöf A. Validation of an extended version of the seiqol-dw in a cohort of hodgkin lymphoma' survivors. Quality of life Research. 2005; 14 (10): 2329–2333.Wettergren L., Björkholm M., Langius-Eklöf A. Validation of an extended version of the seiqol-dw in a cohort of hodgkin lymphoma' survivors. Quality of life Research. 2005; 14 (10): 2329–2333.Krieger N., Strong E., Makosky C., Weuve J. Breast cancer, birth cohorts, and Epstein–Barr virus: methodological issues in exploring the ‘hygiene hypothesis’ in relation to breast cancer, Hodgkins disease, and stomach cancer. Cancer Epidemiol. Biomark. Prev. 2003; 12: 405–411. Aleman B.M., Raemaekers J.M., Tirelli U. et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N. Engl. J. Med. 2003; 348: 2396–2406.Krieger N., Strong E., Makosky C., Weuve J. Breast cancer, birth cohorts, and Epstein–Barr virus: methodological issues in exploring the ‘hygiene hypothesis’ in relation to breast cancer, Hodgkins disease, and stomach cancer. Cancer Epidemiol. Biomark. Prev. 2003; 12: 405–411. Aleman B.M., Raemaekers J.M., Tirelli U. et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N. Engl. J. Med. 2003; 348: 2396–2406.Лимфома Ходжкина. Под ред. В.П. Харченко. М.: Русское слово, 2009.Лимфома Ходжкина. Под ред. В.П. Харченко. М.: Русское слово, 2009.Schimpff S., Diggs C., Wiswell J. et al. Radiation-related thyroid dysfunction: implications for the treatment of Hodgkin's disease. Pediatr. Blood Cancer. 2011; 57: 166–168.Schimpff S., Diggs C., Wiswell J. et al. Radiation-related thyroid dysfunction: implications for the treatment of Hodgkin's disease. Pediatr. Blood Cancer. 2011; 57: 166–168.Robison L., Bhatia S., Ramsay N. et al. Thyroid abnormalities after therapy for Hodgkin’s disease in childhood. The Oncologist. 1996; 1 (1): 62–67.Robison L., Bhatia S., Ramsay N. et al. Thyroid abnormalities after therapy for Hodgkin’s disease in childhood. The Oncologist. 1996; 1 (1): 62–67.Hancock S., Cox R., McDougall I. Thyroid diseases after treatment of Hodgkin's disease. N. Engl. J. Med. 1991; 325: 599–605.Hancock S., Cox R., McDougall I. Thyroid diseases after treatment of Hodgkin's disease. N. Engl. J. Med. 1991; 325: 599–605.Demirkaya M., Sevinir B., Saglam H. et al. Thyroid functions in long-term survivors of pediatric Hodgkin’s lymphoma treated with chemotherapy and radiotherapy. J. Clin. Res. Pediatr. Endocrinol. 2011; 3: 89–94.Demirkaya M., Sevinir B., Saglam H. et al. Thyroid functions in long-term survivors of pediatric Hodgkin’s lymphoma treated with chemotherapy and radiotherapy. J. Clin. Res. Pediatr. Endocrinol. 2011; 3: 89–94.Sklar C., Whitton J., Mertens A. et al. Abnormalities of the thyroid in survivors of Hodgkin’s disease: data from the Childhood Cancer Survivor Study. J. Clin. Endocrinol. Metab. 2000; 85: 3227–3232.Sklar C., Whitton J., Mertens A. et al. Abnormalities of the thyroid in survivors of Hodgkin’s disease: data from the Childhood Cancer Survivor Study. J. Clin. Endocrinol. Metab. 2000; 85: 3227–3232.Acharya S., Sarafoglou K., LaQuaglia M. et al. Thyroid neoplasms after therapeutic radiation for malignancies during childhood or adolescence. Cancer. 2003; 97: 2397–2403.Acharya S., Sarafoglou K., LaQuaglia M. et al. Thyroid neoplasms after therapeutic radiation for malignancies during childhood or adolescence. Cancer. 2003; 97: 2397–2403.Shafford E., Kingston J., Healy J. et al. Thyroid nodular disease after radiotherapy to the neck for childhood Hodgkin's disease. Br. J. Cancer. 1999; 80: 808–814.Shafford E., Kingston J., Healy J. et al. Thyroid nodular disease after radiotherapy to the neck for childhood Hodgkin's disease. Br. J. Cancer. 1999; 80: 808–814.Hunger S., Link M., Donaldson S. ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: the Stanford experience. J. Clin. Oncol. 1994; 12: 2160–2166.Hunger S., Link M., Donaldson S. ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: the Stanford experience. J. Clin. Oncol. 1994; 12: 2160–2166.Nair N., Advani S. Follow up of alterations in thyroid hormones and thyrotropin in patients of Hodgkin's diseasegiven mantle radi- ation. J. Assoc. Physicians. India. 1990; 38: 623–624.Nair N., Advani S. Follow up of alterations in thyroid hormones and thyrotropin in patients of Hodgkin's diseasegiven mantle radi- ation. J. Assoc. Physicians. India. 1990; 38: 623–624.Moryl-Bujakowska A., Balwierz W., Sztefko K. Preliminary results of thyroid function assessment in children and adolescents with Hodgkin's disease treated according to PGP-HD-97 protocol. Przegl. Lek. 2004; 61: 81–84.Moryl-Bujakowska A., Balwierz W., Sztefko K. Preliminary results of thyroid function assessment in children and adolescents with Hodgkin's disease treated according to PGP-HD-97 protocol. Przegl. Lek. 2004; 61: 81–84.Constine L., Donaldson S., McDougall I. et al. Thyroid dysfunction after radiotherapy in children with Hodgkin's disease. Cancer. 1984; 53: 878–883.Constine L., Donaldson S., McDougall I. et al. Thyroid dysfunction after radiotherapy in children with Hodgkin's disease. Cancer. 1984; 53: 878–883.Lin H.M., Teitell M.A. Second malignancy after treatment of pediatric Hodgkin disease. Pediatr. Hematol. Oncol. 2005; 27: 28–36.Lin H.M., Teitell M.A. Second malignancy after treatment of pediatric Hodgkin disease. Pediatr. Hematol. Oncol. 2005; 27: 28–36.Bhatia S., Yasui Y., Robison L. et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J. Clin. Oncol. 2003; 21: 4386–4394.Bhatia S., Yasui Y., Robison L. et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J. Clin. Oncol. 2003; 21: 4386–4394.Constine L.S., Tarbell N., Hudson M.M. et al. Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose. Int. J. Radiat. Oncol. Biol. Phys. 2008; 72: 24–33.Constine L.S., Tarbell N., Hudson M.M. et al. Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose. Int. J. Radiat. Oncol. Biol. Phys. 2008; 72: 24–33.Capra M., Hewitt M., Radford M. et al. Children's Cancer and Leukaemia Group. Long-term outcome in children with Hodgkin's lymphoma: the United Kingdom Children's Cancer Study Group HD82 trial. Eur. J. Cancer. 2007; 43: 1171–1179.Capra M., Hewitt M., Radford M. et al. Children's Cancer and Leukaemia Group. Long-term outcome in children with Hodgkin's lymphoma: the United Kingdom Children's Cancer Study Group HD82 trial. Eur. J. Cancer. 2007; 43: 1171–1179.Metzger M.L., Howard S.C., Hudson M.M. et al. Natural history of thyroid nodules in survivors of pediatric Hodgkin lymphoma. Pediatr. Blood Cancer. 2006; 46: 314–319.Metzger M.L., Howard S.C., Hudson M.M. et al. Natural history of thyroid nodules in survivors of pediatric Hodgkin lymphoma. Pediatr. Blood Cancer. 2006; 46: 314–319.Brabant G., Toogood A., Shalet S. et al. Hypothyroidism following childhood cancer therapy – an under diagnosed complication. Int. J. Cancer. 2012; 130: 1145–1150.Brabant G., Toogood A., Shalet S. et al. Hypothyroidism following childhood cancer therapy – an under diagnosed complication. Int. J. Cancer. 2012; 130: 1145–1150.Vogelius I.R., Bentzen S.M., Maraldo M.V. et al. Risk factors for radiation-induced hypothyroidism: a literature-based meta-analy- sis. Cancer. 2011; 117: 5250–5260.Vogelius I.R., Bentzen S.M., Maraldo M.V. et al. Risk factors for radiation-induced hypothyroidism: a literature-based meta-analy- sis. Cancer. 2011; 117: 5250–5260.Харченко В.П., Сотников В.М., Щербенко О.И. и др. Возрастные аспекты радиочувствительности щитовидной железы у больных лимфогранулематозом. Пробл. эндокринол. 1998; 2: 19–21.Харченко В.П., Сотников В.М., Щербенко О.И. и др. Возрастные аспекты радиочувствительности щитовидной железы у больных лимфогранулематозом. Пробл. эндокринол. 1998; 2: 19–21.Metzger M.L., Hudson M.M., Somes G.W. et al. White race as a risk factor for hypothyroidism after treatment for pediatric Hodgkin's lymphoma. J. Clin. Oncol. 2006; 24: 1516–1521.Metzger M.L., Hudson M.M., Somes G.W. et al. White race as a risk factor for hypothyroidism after treatment for pediatric Hodgkin's lymphoma. J. Clin. Oncol. 2006; 24: 1516–1521.Балашов А.Т., Мясников A.A. Заболевания щитовидной железы при комплексном лечении лимфогранулематоза. Эндокринология. 1998; 4: 18.Балашов А.Т., Мясников A.A. Заболевания щитовидной железы при комплексном лечении лимфогранулематоза. Эндокринология. 1998; 4: 18.Devney R.B., Sklar C.A., Nesbit M.E. et al. Serial thyroid function measurements in children with Hodgkin disease. J. Pediatr. 1984; 105: 223–227.Devney R.B., Sklar C.A., Nesbit M.E. et al. Serial thyroid function measurements in children with Hodgkin disease. J. Pediatr. 1984; 105: 223–227.Green E.M., Grecher M.L., Yakar D. et al. Thyroid function in pediatric patients after neck irradiation for Hodgkin’s disease. Med. Pediatr. Oncol. 1980; 8: 127–136.Green E.M., Grecher M.L., Yakar D. et al. Thyroid function in pediatric patients after neck irradiation for Hodgkin’s disease. Med. Pediatr. Oncol. 1980; 8: 127–136.Glatstein E., McHardy-Young S., Brast N. et al. Alterations in serum thyrotropin and thyroid function following radiotherapy in patients with malignant lymphoma. J. Clin. Endocrinol. Metab. 1971; 32: 833–884.Glatstein E., McHardy-Young S., Brast N. et al. Alterations in serum thyrotropin and thyroid function following radiotherapy in patients with malignant lymphoma. J. Clin. Endocrinol. Metab. 1971; 32: 833–884.Shalet S.M., Rosenstock J.D., Beardwell C.G. et al. Thyroid dysfunction after external irradiation to the neck for Hodgkin’s disease in childhood. Clin. Radiol. 1977; 28: 511–515.Shalet S.M., Rosenstock J.D., Beardwell C.G. et al. Thyroid dysfunction after external irradiation to the neck for Hodgkin’s disease in childhood. Clin. Radiol. 1977; 28: 511–515.Smith R.E., Adler A.R., Clark P. et al. Thyroid function after mantle irradiation in Hodgkin’s disease. JAMA. 1981; 245: 46.Smith R.E., Adler A.R., Clark P. et al. Thyroid function after mantle irradiation in Hodgkin’s disease. JAMA. 1981; 245: 46.Nelson D.F., Reddy K.V., O’Mara R.E. et al. Thyroid abnormalities following neck irradiation for Hodgkin’s disease. Cancer. 1978; 42: 2553–2562.Nelson D.F., Reddy K.V., O’Mara R.E. et al. Thyroid abnormalities following neck irradiation for Hodgkin’s disease. Cancer. 1978; 42: 2553–2562.Smith R.E., Adler A.R., Clark P. et al. Thyroid function after mantle irradiation in Hodgkin’s disease. JAMA. 1981; 245: 46–49.Smith R.E., Adler A.R., Clark P. et al. Thyroid function after mantle irradiation in Hodgkin’s disease. JAMA. 1981; 245: 46–49.Massimino M., Gandola L., Pignoli E. et al. TSH suppression as a possible means of protection against hypothyroidism after irradiation for childhood Hodgkins lymphoma. Pediatr. Blood Cancer. 2011; 57: 166–168.Massimino M., Gandola L., Pignoli E. et al. TSH suppression as a possible means of protection against hypothyroidism after irradiation for childhood Hodgkins lymphoma. Pediatr. Blood Cancer. 2011; 57: 166–168.Li Y.Q., Chen P., Haimovitz-Friedman A. et al. Endotelian apoptosis initiates acute blood-brain barrier disruptions after ionizing radiation. Cancer Res. 2003; 63: 5950–5956.Li Y.Q., Chen P., Haimovitz-Friedman A. et al. Endotelian apoptosis initiates acute blood-brain barrier disruptions after ionizing radiation. Cancer Res. 2003; 63: 5950–5956.Roedmann H.P., Blaese M.A. Responses of normal cells to ionizing radiation. Semin Radiat. Oncol. 2007; 17: 81–88.Roedmann H.P., Blaese M.A. Responses of normal cells to ionizing radiation. Semin Radiat. Oncol. 2007; 17: 81–88.Nishiyama K., Kozuka T., Higashihara T. et al. Acute radiation thyroiditis. Int. J. Radiat. Oncol. Biol. Phys. 1996; 36: 1221–1224.Nishiyama K., Kozuka T., Higashihara T. et al. Acute radiation thyroiditis. Int. J. Radiat. Oncol. Biol. Phys. 1996; 36: 1221–1224.

The authors declare that there are no conflicts of interest present.